Clozapine in the management of schizophrenia. Clozapine has unique pharmacological profile.

Por Dursun, S M, Reveley, M A
Publicado em 1993

Human platelet monoamine oxidase activity in health and disease: a review.

Por Sandler, M, Reveley, M A, Glover, V
Publicado em 1981

Refractory symptomatic schizophrenia resulting from frontal lobe lesion: response to clozapine.

Por Burke, J G, Dursun, S M, Reveley, M A
Publicado em 1999

Low serum cholesterol and depression.

Por Dursun, S. M., Burke, J. G., Reveley, M. A.
Publicado em 1994

Cholesterol and violent death. Other studies exist.

Por Boston, P. F., Dursun, S. M., Reveley, M. A.
Publicado em 1994

The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study.

Por Dursun, S M, Szemis, A, Andrews, H, Reveley, M A
Publicado em 1999

Absence of platelet monamine oxidase inhibition during amitriptyline or zimelidine treatment.

Por Reveley, M A, Glover, V, Slander, M, Coppen, A
Publicado em 1979

Effects of typical antipsychotic drugs and risperidone on the quality of sleep in patients with schizophrenia: a pilot study.

Por Dursun, S M, Patel, J K, Burke, J G, Reveley, M A
Publicado em 1999

Effects of clozapine and typical antipsychotic drugs on plasma 5-HT turnover and impulsivity in patients with schizophrenia: a cross-sectional study.

Por Dursun, S M, Szemis, A, Andrews, H, Whitaker, P, Reveley, M A
Publicado em 2000